This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data
Learn about funding and reimbursement for England, Scotland, Wales and Northern Ireland
Scroll through our resources about acromegaly management, patient resources, and experience with acromegaly
Menu
Close
Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data
Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
MRI analysis showed a low incidence for tumour volume increase suggesting this is not promoted by pegvisomant treatment.1
- 2162 patients analysed for pituitary imaging
Changes in Tumour Size via Local and Central MRI Analysis:1
1795 patients were reported to have ≥1 pituitary imaging result after pegvisomant initiation
Local MRI Analysis:1
• 28.9% (n=519) of patients showed a change in tumour size (increase, decrease or both)
• 71.1% (n=1276) of patients showed no change in pituitary tumour size
Central MRI Analysis:1
As per the protocol, patients showing a change in tumour size through local MRI analysis were reassessed through a central reader. This was not required during the voluntary extension phase of the study.
• 264 out of 519 patients were re-assessed for a change in tumour size via central analysis
• 3% (54/1795) of patients showed an increase in tumour size
• 0.7% (12/1795) of patients showed an increase and decrease in tumour size
Changes in pituitary tumour size were reported as AEs of special interest in 96 (4.3%) of cases (24 (1.1%) considered treatment related) and caused 31 (1.4%) patients to discontinue pegvisomant treatment.1
To find out more about supporting your patients or to order starter kits
Help find your patient's personal optimum by titrating doses
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024